ArticleScientific reports2025
The burden of age-related macular degeneration and its socioeconomic associates in the Eastern Mediterranean Region from 1990 to 2021.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This research aimed to assess the trends in the burden of age-related macular degeneration (AMD) in the Eastern Mediterranean Region (EMR) by age, sex, socio-demographic index (SDI), and location. We extracted data on the prevalence and years lived with disability (YLDs) of AMD from the Global Burden of Disease (GBD) study 2021. The data included all 22 countries in the EMR from 1990 to 2021. Estimates were presented as counts, age-standardized rates per 100,000, and their corresponding 95% uncertainty intervals (UIs). In 2021, the EMR had an age-standardized point prevalence for AMD of 196.8 (95% UI: 161.5 to 240.2) and a YLD rate of 14.9 (10.3 to 20.5) per 100,000 individuals, which represents a decline of 8.1% (from - 11.1% to -5.0%) and 13.3% (from - 16.7% to -9.7%), respectively, when compared to the data from 1990. In 2021, Iran exhibited the highest age-standardized YLD rate at 25.0 (17.2 to 34.9), while Somalia recorded the lowest rate at 8.0 (5.2 to 11.8). Notably, all countries within the EMR demonstrated a reduction in their age-standardized YLD rates from 1990 to 2021, except Yemen. We found an M-shaped relationship between AMD burden and the SDI during 1990-2021. The burden initially increased until reaching an SDI of 0.3, followed by a decline to 0.4, then rose again, peaking at an SDI of 0.6, before showing a final descending trend at SDI values. Despite a reduction in the burden of AMD over the past thirty years, its prevalence continues to be remarkable. Our findings revealed that women experienced a greater burden of AMD than men in the EMR. Additionally, this study highlighted a reduction in age-standardized prevalence and YLD rates. These insights can serve as a foundational basis for developing policies aimed at preventing and treating AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.